Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Solar, Inc. (FSLR) vs Smith & Nephew plc (SNN) Price & Performance

First Solar, Inc.Trade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

First Solar, Inc. vs Smith & Nephew plc — how do they compare? First Solar, Inc. trades at $226.75 (market cap $25.89B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: First Solar, Inc. is far larger — about 2.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.65% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals.

FSLRSNN
Market Cap
$25.89B$12.54B
Sector
TechnologyHealth
52-Week High
$318.30$38.70
52-Week Low
$180.05$28.73
Enterprise Value
$24.36B$15.57B
Dividend Yield
2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Solar, Inc.

First Solar (FSLR) trades at $228.27, down 4.62% on the day, amid mixed signals. The stock shows a bullish technical trend with strong moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported robust revenue growth to $5.22B in 2025, with a net income margin of 29.27%, while recent earnings beat expectations in Q1 and Q2 2026. However, multiple class-action lawsuits filed in August 2026 create near-term legal overhang.

The outlook remains positive given analyst consensus favoring a buy rating with a $282.07 price target, implying significant upside. Key risks include legal proceedings and competitive pressures in the solar sector. Earnings growth and operational cash flow strength support long-term value, but investors should weigh legal uncertainties against fundamental strengths.

Smith & Nephew plc

SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.

The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.

Returns comparison

Trailing returns across standard periods

About First Solar, Inc.

First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.

Read more on FSLR

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN